BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25766836)

  • 41. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.
    Sun HY; Ji FQ
    Biochem Biophys Res Commun; 2012 Jun; 423(2):319-24. PubMed ID: 22659414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.
    Sun H; Li Y; Li D; Hou T
    J Chem Inf Model; 2013 Sep; 53(9):2376-89. PubMed ID: 23952683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
    Liu Q; Kan Y; Zhao Y; He H; Kong L
    Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML.
    Dawson AJ; Bal S; McTavish B; Tomiuk M; Schroedter I; Ahsanuddin AN; Seftel MD; Vallente R; Mai S; Cotter PD; Hovanes K; Gorre M; Gunn SR
    Cancer Genet; 2011 Jun; 204(6):344-7. PubMed ID: 21763633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutically Targetable ALK Mutations in Leukemia.
    Maxson JE; Davare MA; Luty SB; Eide CA; Chang BH; Loriaux MM; Tognon CE; Bottomly D; Wilmot B; McWeeney SK; Druker BJ; Tyner JW
    Cancer Res; 2015 Jun; 75(11):2146-50. PubMed ID: 26032424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
    Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
    APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review.
    Tirado CA; Valdez F; Klesse L; Karandikar NJ; Uddin N; Arbini A; Fustino N; Collins R; Patel S; Smart RL; Garcia R; Doolittle J; Chen W
    Cancer Genet Cytogenet; 2010 Jul; 200(1):54-9. PubMed ID: 20513535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.
    Kim SM; Kim MJ; Jung HA; Sun JM; Choi YL; Ko YH; Park K; Baek CH; Son YI; Ahn MJ
    Head Neck; 2015 May; 37(5):E66-9. PubMed ID: 25270523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
    Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
    PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.
    Gambacorti-Passerini C; Mussolin L; Brugieres L
    N Engl J Med; 2016 Jan; 374(1):95-6. PubMed ID: 26736010
    [No Abstract]   [Full Text] [Related]  

  • 59. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
    Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
    Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase.
    Kumar A; Shanthi V; Ramanathan K
    Mol Inform; 2015 Feb; 34(2-3):105-14. PubMed ID: 27490033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.